Alnylam Pharmaceuticals Inc. (ALNY)
NASDAQ: ALNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALNY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $19.26B
- P/E (TTM)
- 7.26
- Forward P/E
- 14.51
- EPS (TTM)
- $19.80
- Dividend yield
- None
- 52-week range
- 143.40 – 479.79
- Day range
- 143.40 – 151.41
- Volume / Avg
- 2.33M / 2.09M
- Beta
- —
- Shares outstanding
- 133.94M
52-week range
ALNY stock today
Shares of Alnylam Pharmaceuticals (ALNY) finished lower on Nov 20 at $143.82, a drop of 2.71% or $4.00 per share, versus the S&P 500's 3.70% decline. At this level, ALNY sits near the bottom of its 52-week range of $143.40 to $479.79: 70.0% below the high, set on Dec 3, 2025 and 0.3% above the low. ALNY is down 63.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.0%.
At 7.3x trailing earnings, Alnylam Pharmaceuticals trades below the peer-group median of 31.2x. Its forward P/E of 14.5x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Alnylam Pharmaceuticals
Company profileAlnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Yvonne L. Greenstreet M.B.A., M.D.
- Headquarters
- Cambridge, MA
- Employees
- 2,500
- IPO year
- 2004
- Website
- alnylam.com
Financial highlights
Full financialsIn fiscal 2025, Alnylam Pharmaceuticals generated $3.71 billion in revenue, up 65.2% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $313.7 million, for a net margin of 8.4% versus a median of -101.0% in the prior 5 years. Gross margin was 81.8% (down from 86.4%) and operating margin 13.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.29M |
| Growth | +65.19% | +22.97% | +76.23% | +22.88% | +71.31% |
| Net income | $313.75M | $-278.16M | $-440.24M | $-1.13B | $-852.82M |
| EPS (diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Analyst forecast
ForecastConsensus (30 analysts)
buy
Avg. price target
$289.22+101.10%
- Strong buy 7
- Buy 14
- Hold 9
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $15.72 vs $1.46
- Surprise
- +976.71%
ALNY news
All ALNY news- Alnylam Pharmaceuticals Expands Sales Force to Accelerate AMVUTTRA DemandNasdaq
- REGN Gets FDA Nod for Livsayis in Generalized Myasthenia GravisNasdaqREGN, ALNY, VCEL, ETON
- Alnylam Pharma To Receive $25 Mln Payment From Regeneron On FDA Approval Of LivsayisNasdaq
- Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Noteworthy Friday Option Activity: ALNY, SMCI, BURLNasdaqALNY, SMCI, BURL
- Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 EarningsNasdaqIONS, AZN, ALNY
- Alnylam's AMVUTTRA Shows Sustained Benefits Through Five Years In ATTR-CMNasdaq
- Alnylam Pharmaceuticals, Inc. Announces $1.0 Billion Share Repurchase Program and Departure of Chief Commercialization Officer Tolga TangulerNasdaq
Alnylam Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ASNDAscendis Pharma A/S | 252.73 | -1.26% | $16.58B | vs ALNY |
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs ALNY |
| UTHRUnited Therapeutics Corporation | 554.73 | -0.78% | $23.63B | vs ALNY |
| BBIOBridgeBio Pharma Inc. | 76.03 | -2.75% | $14.81B | vs ALNY |
| JAZZJazz Pharmaceuticals plc | 230.26 | -2.62% | $14.78B | vs ALNY |
| ELANElanco Animal Health Incorporated | 25.74 | -2.09% | $12.87B | vs ALNY |
| RDYDr. Reddy's Laboratories Ltd | 14.89 | +0.40% | $12.41B | vs ALNY |
| BMRNBioMarin Pharmaceutical Inc. | 60.41 | -1.64% | $11.70B | vs ALNY |
Indexes, lists and sector
Index membership
Alnylam Pharmaceuticals stock FAQ
What is Alnylam Pharmaceuticals's stock price today?
ALNY last traded at $143.82 as of Nov 20, 4:00 PM EST, down 2.71% on the day. Prices are delayed at least 15 minutes.
What is ALNY's P/E ratio?
ALNY trades at a trailing P/E ratio of 7.26 and a forward P/E of 14.51, compared with a median of 31.2 for its closest peers.
Is Alnylam Pharmaceuticals in the S&P 500?
No. Alnylam Pharmaceuticals is not currently a member of the S&P 500; it is included in the NDX.
Who is Alnylam Pharmaceuticals's CEO?
Dr. Yvonne L. Greenstreet M.B.A., M.D. is the chief executive officer of Alnylam Pharmaceuticals Inc., which has about 2,500 employees.
What is the ALNY 52-week high?
The 52-week high for ALNY is $479.79 and the 52-week low is $143.40. The stock is currently 70.0% below its high.